NCT03082690View on ClinicalTrials.gov

ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

May 30, 2019

Study Completion Date

June 2, 2019

Conditions
HIV Prevention
Interventions
DRUG

DuoGel

1% IQP-0528 in gel formulation

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors
All Listed Sponsors
collaborator

ImQuest Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Johns Hopkins University

OTHER